Bayer HealthCare, a global enterprise with core competencies in the
fields of health care, agriculture and high-tech materials, has applied
for marketing authorisation of aflibercept solution for injection for
the treatment of patients with visual impairment due to macular edema
secondary to branch retinal vein occlusion (BRVO) to the European
Medicines Agency (EMA).
Aflibercept solution for injection into the eye has already been approved under the brand name Eylea for the treatment of patients with neovascular age-related macular degeneration (wet AMD) and the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Bayer has already filed for marketing authorisation for the treatment of diabetic macular edema (DME).
Aflibercept solution for injection into the eye has already been approved under the brand name Eylea for the treatment of patients with neovascular age-related macular degeneration (wet AMD) and the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). Bayer has already filed for marketing authorisation for the treatment of diabetic macular edema (DME).
No comments:
Post a Comment